

https://journalrip.com

doi: 10.34172/jrip.2024.32197

Journal of Renal Injury Prevention

# Association of AT1R (A1166C) gene polymorphisms and hypertension: A study in south Indian population and meta-analysis



Amulya Ramakrishnegowda<sup>1</sup>, Sandhya Suresh<sup>1</sup>, Ramprasad Elumalai<sup>1</sup>, Harini Ravi<sup>2</sup>, Gnanasambandan Ramanathan<sup>2</sup>

<sup>1</sup>Department of Nephrology, Sri Ramachandra Institute of Higher Education and Research, Porur, Chennai-600116, India <sup>2</sup>School of BioSciences and Technology, Vellore Institute of Technology, Vellore-632014, India

ARTICLEINFO	A B S T R A C T						
Article Type: Original	<b>Introduction:</b> Hypertension is a multi-factorial disease caused by several etiologies. It has been reported that hypertension has been linked to AT1R A1166C polymorphism, but the						
<i>Article History:</i> Received: 30 Apr. 2023 Accepted: 15 Jun. 2023 Published online: 28 Apr. 2024	<ul> <li>previous studies in Indian populations remain controversial.</li> <li>Objectives: In this study, we aimed to investigate the AT1R A1166C gene polymorphism with the risk of hypertension in the south Indian populations.</li> <li>Patients and Methods: The 179 subjects were considered in the association study utilizing polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) genotyping technique, yielding no significant association in the dominant and allelic models</li> </ul>						
Keywords:	P=0.76 and $P=0.76$ respectively. Additionally, to determine the relationship between the						
Hypertension	AT1R gene A1166C polymorphism and hypertension in the Indian population, a meta-						
Polymorphism	analysis was conducted. The retrieved seven case-control studies on Indian populations are						
AT1R gene	conducted to determine how strongly genes are associated using the pooled odds ratio (OR)						
Meta analysis	and 95% confidence intervals (CI).						
Indian population	Results: The meta-analysis was performed by RevMan software and significant association						
A1166C	was observed in the dominant (AA versus AC+CC, $P=0.05$ ), recessive (CC versus AA+AC,						
	P=0.02) and allelic (A versus C, $P=0.04$ ) models respectively.						
	Conclusion: The 'C' allele is statistically associated with an elevated hypertension risk in						
	Indian populations.						

#### *Implication for health policy/practice/research/medical education:*

The south Indian population case-control study reveals no relationship between the AT1R gene A1166C polymorphism and hypertension. However, the Indian meta-analysis study reveals the 'C' allele of A1166C polymorphism is statistically associated with elevated hypertension risk.

*Please cite this paper as:* Ramakrishnegowda A, Suresh S, Elumalai R, Ravi H, Ramanathan G. Association of AT1R (A1166C) gene polymorphisms and hypertension: a study in south Indian population and meta-analysis. J Renal Inj Prev. 2024; x(x): e32197. doi: 10.34172/jrip.2024.32197.

# Introduction

The renin-angiotensin-aldosterone system (RAAS) alteration was accountable for the development and progression of cardiovascular disease, progressive kidney disease, and essential hypertension, (1). Among several genes studied in the RAAS, the angiotensin II type 1 receptor (AT1R) gene polymorphisms are biologically and clinically relevant to the pathogenesis and progression of renal disease and related to hypertension (2). Among

several polymorphic sequence variants of the AGTR1 gene, the A1166C (rs5186), a trans version at 1166, is positioned in the 3'-Untranslated Region (3) and was the most well-studied in different populations. According to the reporter silencing assays, the 1166C allele lowers the miR-155 interaction with the cis-regulatory region and disrupts its base-pairing complementarity (4). Furthermore, a logarithm of the odds (LOD) score of 2.9 validates that the AGTR1 gene variants and hypertension

#### are associated (5).

The data concerning the AT1R gene polymorphisms and hypertension found a significant association in Caucasians (6), and Asian populations (7). While the Nigerian (8), Kazakans (9), and Japanese (10) populations showed a lack of association. Furthermore, the study in South Indian Tamilian population (11) showed no association with essential hypertension. However, the other study conducted in North Indian Populations suggested that the AT1R A1166C gene C allele is linked with essential hypertension and its upregulation could play a vital role in it (12). In addition, early studies revealed inconsistent results with the correlation between the AT1R C 1166 allele and hypertension risk. Therefore, the study aimed to determine the AT1R gene polymorphisms, involved in the increased risk of developing hypertension in the South Indian population. Further, a meta-analysis was performed on data concerning Indian population to unravel the possible association between hypertension and A1166C polymorphisms of the AT1R gene.

#### **Objectives**

This case-control study is designed to investigate the AT1R A1166C gene polymorphism with the risk of hypertension and to perform the meta-analysis on the data concerning South Indian populations.

# Patients and Methods

# Study design

This case-control study consists of 179 subjects [70 hypertensive patients (61.4% of men) and 109 healthy volunteers as control (non-hypertensives) (60.6% of men)], recruited from Sri Ramachandra medical college and research institute, Chennai, Tamil Nādu, India. All subjects are from the geographical region of Tamil Nadu within south Indian origin. The demographic characteristics and clinical and biochemical variables were collected from all study subjects. The hypertensive subjects fulfilled the systolic blood pressure >140 mm Hg and a diastolic blood pressure >90 mm Hg. The 3 mL of blood sample was collected from all study participants.

# **Determination of genotypes**

phenol-chloroform extraction The and ethanol precipitation method was used to isolate human genomic DNA from peripheral blood (13). The human AT1R A1166C variant sequence was detected with the specific primers: forward: GCACCATGTTTTGAGGTTG and reverse: CGACTACTGCTTAGCATA. The PCR process included an initial denaturation step in the thermocycler at 94°C for 10 min., followed by the PCR cycle which was repeated 35 times. This included denaturation at 94°C for 1 minute, annealing at 72°C for 1 minute and extension at 72°C for 10 minutes. The PCR products were digested with 10U DdeI restriction enzyme and then visualized on 2% agarose gels. For CC genotypes 417, 110, and 13 bp

fragments were obtained and AA genotypes 527 and 13 bp PCR products were obtained.

## Literature search strategy for meta-analysis

The computerized literature search was performed in various databases like PubMed, Google Scholar, and Scopus using key terms: "AT1R", "hypertension", "A1166C", "Indian population", "rs5186", "polymorphism" to retrieve the articles published exclusively in Indian population on AT1R A1166C polymorphism with hypertension till January 2023. Further, the retrieved articles were admitted to checking the eligibility with inclusion and exclusion criteria for the meta-analysis as mentioned in Figure 1.

#### Statistical analysis

The allelic and genotypic frequencies of AT1R A1166C polymorphism were evaluated using the gene-counting method. The  $\chi^2$  test with one degree of freedom was performed to test the Hardy-Weinberg equilibrium. Meanwhile, P < 0.05 was considered significant. The association between the candidate gene polymorphism and hypertension was determined by the  $\chi^2$  association test. Statistical analysis was done using SPSS for Windows 10.1 (SPSS Inc., Chicago, IL), and for meta-analysis, the Cochrane Rev Man software version 5.4 (Cochrane library, UK) was used for testing heterogeneity and publication bias.

# Results

#### **Baseline clinical characteristics**

Hundred and seventy-nine study subjects were included and genotyped in this present study. Of the genotyped individuals, the mean age of the subjects was  $46.9 \pm 10.4$ years. The differences in age among the subjects were shown to have statistical significance (P=0.001). The studied characteristics of the groups were demonstrated in Table 1. Among the studied characteristics the creatinine (P<0.001), BUN (P<0.001), bicarbonate (P=0.003), potassium (P=0.039), and calcium (P<0.001) were found to have significant relation between hypertension and control groups. However, there were no significant differences between the other examined characteristics of sodium (P=0.982) and chloride (P=0.900; Table 1).

### AT1R A1166C genotypes and hypertension

Among the subjects, 109 (60.9 %) individuals are nonhypertensive (male: 60.6%), and 70 (39.1%) individuals belong to hypertensive group (male: 61.4) and found no significant association (P=0.906). The genotype distribution between controls and hypertensive groups revealed that there was no significant association; AA versus AC, OR=1.18, 95% CI=0.39-3.56, and P=0.764. Furthermore, the allelic model revealed no significant association; A versus C, OR=1.17, 95% CI=0.39-3.46, and P=0.769. However, it was found that there was a significant association in the family history of diabetes




Figure 1. Schematic representation of the article selection process.

mellitus between the study groups (P=0.001; Table 2).

#### Study characteristics of meta-analysis

A total of 146 papers were retrieved from the mentioned databases published till January 2023. The review papers, meta-analyses, systematic reviews, book chapters, and molecular studies other than the Indian population were excluded from this analysis. Upon screening, seven case-control studies with 2750 individuals (hypertensives;1381 and non-hypertensives: 1369) from Indian populations fulfilled the criteria and were considered for the present meta-analysis. The retrieved information for the hypertensive cases and controls from the Indian population of their genotypes, allele frequencies, and Hardy-Weinberg equilibrium were documented in Table 3.

#### Meta-analysis

The analysis between hypertensive cases versus controls

Table 1 Clinical characteristics of study participants

of AT1R A1166C polymorphism revealed substantial heterogeneity in the dominant ( $I^2 = 69\%$ ) and recessive ( $I^2 = 65\%$ ) models and high heterogeneity was noticed in allelic ( $I^2 = 75\%$ ) model. The random-effect model (DerSimonian Liard) was adopted based on heterogeneity values, a significant association with hypertensive risk in dominant (AA versus AC+CC) (Q test, P=0.002, OR = 1.41, 95%: CI 1.01-1.98, overall effect: P=0.05) and recessive (CC versus AA+AC) (Q test, P=0.02, OR = 0.56, 95% CI: 0.34-0.92, and overall effect: P=0.02). Similar to the genotype meta-analysis, the pooled odds ratio for the allelic model (C versus A) showed a statistically significant association with hypertensive cases adopting random effect (Q test, P=0.002, OR = 1.38, 95% CI: 1.02-1.85, overall effect: P=0.04) among Indian population (Figure 2).

#### **Publication bias**

In addition the publication bias of the literature was

Clinical characteristics	Controls (n=109) Mean ±SD	Hypertensive cases (n=70) Mean ±SD	P value*	
Age (y)	52.6 ± 12.7	46.9 ± 10.4	<0.001	
BUN (mg/dL)	13.5 ± 6.5	18.0 ± 9.0	<0.001	
Creatinine (mg/dL)	$1.1 \pm 1.1$	3.0 ± 2.6	<0.001	
Sodium (mmol/L)	136.0 ± 6.6	135.8 ± 9.0	0.982	
Potassium (mmol/L)	3.9 ± 0.6	4.4 ± 2.3	0.039	
Chloride (mmol/L)	101.1 ± 6.1	100.9 ± 11.8	0.900	
Bicarbonate (mmol/L)	24.5 ± 3.9	22.8 ± 4.4	<0.003	
Calcium (mg/dL)	9.9 ± 1.7	7.7 ± 1.2	<0.001	

BUN, bun urea nitrogen. \* t test.

Genotypes		Control (n=109) (%)	Hypertensive (n=70) (%)	OR (95 % CI)	P value	
AA		101 (92.6)	64 (91.4)	Reference		
AC		8 (7.3)	6 (8.57)	1.18 (0.39 – 3.56)	0.764	
CC		0 (0)	0 (0)	-	-	
A		210 (96.3)	134 (95.7)	Reference		
С		8 (3.6)	6 (4.3)	1.17 (0.39 – 3.46)	0.769	
Candan	Male	66 (60.6)	43 (61.4)	Reference		
Gender	Female	43 (39.4)	27 (38.6)	0.96 (0.52 – 1.78)	0.906	
	No	103 (94.5)	43 (61.4)	Reference		
FH-DM	Yes	6 (5.5)	27 (38.6)	10.77 (4.15 – 27.9)	0.001	

FH-DM, family history of diabetes mellitus; OR, odds ratio; CI, confidence interval.

analyzed in this study using Begg's funnel plot. The standard error and the odds ratio from the genetic models were conducted to generate the funnel plot. Figure 3 depicts the test performed in the analyzed genetic models and the symmetrical funnel plots denoted no evidence of publication bias for AT1R A1166C polymorphism in Indian population studies (Figure 3).

#### Discussion

4

In this present study, the AT1R gene did not have a strong association with hypertension in the south Indian population. The performed meta-analysis of AT1R A1166C polymorphism in controls and hypertensive cases showed a significant association in Indian populations. Additionally, heterogeneity among the studies depicted that all the dominant, recessive, and allelic genetic models

revealed substantial heterogeneity. The publication bias was not reported.

The studies conducted on AT1R gene polymorphisms in association with hypertension in Indian populations yielded inconsistent results. Studies conducted by Chandra et al, in northern Indian populations (12), Parchwani et al on Gujarati subjects (14), and Patnaik et al from Odisha (15) explained the significance of polymorphism of the AT1R gene with the elevated hypertension risk. However, in contradiction to this, studies from Chandigarh by Chaudhary and Chaudhary (16), Ramu et al (11) on the south Indian population, Ashavaid et al on Mumbai individuals (17), and south Indian populations (18) failed to substantiate the association between the AT1R gene polymorphism and hypertension. Moreover, global studies found inconsistent results. Studies on Egyptian

$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	А.	Case	e	Contr	ol		Odds Ratio		Odds Ratio		
Ashavaid et al., 2000       14       105       33       192       11.1%       0.74 (D.38, 1.46)         ON parchandra et al., 2014       158       221       1157       20.44 (D.44, 2.23)         ON achandra et al., 2018       101       111       157       69.46 (D.42, 2.33)         Madday et al., 2018       101       111       137       69.46 (D.42, 2.33)         Paraik et al., 2014       40       240       13       170       11.3%       2.42 (1.25, 4.67)         Present study       6       70       8109       6.4%       1.18 (D.39, 3.57)       146         Standard et al., 2021       111       170       14.4%       14.93       19.12 (D.2, 2.89)         Total (95% CI)       1381       1463       100.0%       1.41 (1.01, 1.98)         Total (95% CI)       1381       1463       100.0%       1.41 (1.01, 1.98)         Study or Study cop       Coverts       Total Weight       M4.1 Random, 55% CI       M4.4 Random, 55% CI         Markand et al., 2014       122       116       118       113.13 (D.70, 18.31       M4.4 Random, 55% CI         Markand et al., 2014       123       120       1170       127, 278, 0.15 (100, 12.88)       M4.4 Random, 55% CI         Present study	Study or Subgroup					Weight					
Dhanacharia et al., 2014 123 211 126 211 157% 0.94 (0.94, 1.94) Dhanacharia et al., 2018 158 224 157 257 158% 1.52 (1.94, 2.33) M haday et al., 2018 10 111 13 104 8.6% 0.69 (0.28, 1.86) Present study 6 70 8 109 6.4% 1.19 (0.38, 3.57) S hadi et al., 2014 40 240 13 170 11.3% 2.42 (1.26, 4.87) Present study 6 70 8 109 6.4% 1.19 (0.39, 3.57) S hadi et al., 2014 40 20 55 2.50 152% 2.41 (1.68, 3.46) Total events 101 (1.01, 1.01, 1.02) B. Case Control 0.000, 1.44 (1.02, 1.02) Dhanacharia et al., 2014 10 2.78, et al. 70, e. 0.002, P = 65%. Total events 101 212 (1.17, 2.11) 1138 1143 100.0% 1.41 (1.01, 1.99) Dhanacharia et al., 2014 172 211 168 211 20.15% 0.16 (1.10, 1.83) Dhanacharia et al., 2014 172 211 110 119 22 11 Not estimable Dhanacharia et al., 2014 172 211 110 10 16 192 (1.10, 1.83) Dhanacharia et al., 2014 172 211 110 10 16 192 (1.10, 1.83) Dhanacharia et al., 2014 172 211 111 111 104 104 Not estimable Dhanacharia et al., 2014 172 211 150 170 2.7% 0.15 (0.01, 2.89) Total events 102 113 114 111 110 104 Not estimable Dhanacharia et al., 2014 172 150 128 220 (1.00, 0.31, 0.37) Dhanacharia et al., 2014 172 115 107 2.7% 0.50 (0.34, 0.92) C. Exterior overall effect Z = 1.39 (P = 0.02) C. Exterior overall effect Z = 2.30 (P = 0.02) C. Exterior overall effect Z = 2.30 (P = 0.02) C. Exterior overall effect Z = 2.30 (P = 0.02) C. Case Control Case Control Odds Ratio Odds Ratio Odds Ratio Odds Ratio MH, Random, 95% Cl Athread et al., 2014 162 422 16.7% 0.30 (0.71, 2.8) Dhanacharia, 2014 162 422 16.7% 0.30 (0.31, 0.32) Dhanacharia et al., 2014 162 422 16.7% 0.30 (0.31, 0.32) Dhanacharia et al., 2014 164 163 163 (1.17% 1.17% 1.17, 1.18) Dhanacharia et al., 2014 164 163 163 (1.17% 1.17, 1.14, 1.18) Dhanacharia et al., 2014 164 164 163 163 (1.17% 1.17, 1.14, 1.18) Dhanacharia et al., 2014 164 164 163 163 (1.17% 1.17, 1.14, 1.18) Dhanacharia et al., 2014 164 164 163 163 (1.17% 1.17, 1.14, 1.18) Dhanacharia et al., 2014 164 164 163 163 (1.17% 1.17, 1.14, 1.18) Dhanacharia et al.,		14	105	33	192	11.1%	0.74 (0.38, 1.46)				
DN particular et al., 2018 108 224 157 257 15.8% 15.21 (0.4, 2.23) wheaday et al., 2018 10 11 13 1014 8.6% 0.069 (0.24), 6.80 Panake et al., 2014 40 240 13 170 11.3% 2.42 (1.25, 4.67) Present study 6 70 8 109 6.4% 1.18 (1.90, 33, 57) Standar et al., 2014 149 250 95 250 15.2% 2.41 (1.68, 3.45) Standar et al., 2014 149 250 95 250 15.2% 2.41 (1.68, 3.45) Standar et al., 2014 149 250 95 250 15.2% 2.41 (1.68, 3.45) Spatiel et al., 2021 111 170 84 170 14.9% 13.93 (1.57, 8.45) Total events 151 1529 Heterogenetic: Total = 0.15, Chr <sup>2</sup> = 2.78, dl = 7 ( $P = 0.002$ ); P = 69% Test for overall effect Z = 1.98 ( $P = 0.05$ ) B. Case Control Study or Study control to 5 192 192 192 100 444 170 10 10 10 10 10 10 10 10 10 10 10 10 10		123	211	126	211	15.7%			+		
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $		158	224	157	257						
Panake sia, 2014 40 240 13 170 113% 2421 125, 4677 Present study 6 70 8 109 64% 118 103 3, 357 Schandra et al., 2014 149 250 95 250 152% 241 [168, 345] Schandra et al., 2021 111 170 84 170 149% 1.93 [125, 2.88] Total events 611 529 Hetrogenetic, Tudr = 0.15, Chr <sup>2</sup> = 2.78, df = 7 (P = 0.002); P = 69% Test for overall effect Z = 1.99 (P = 0.05) B. Case Control Weight M4.K Random, 59% C1 Akhnaid et al., 2014 172 211 188 211 26.1% 1.38 [0.04% 1.38] Odds Ratio Odds Ratio Od											
Present tudy $1 = 0$ for $10^{\circ}$ for $10^{$											
8 chandra et al., 2014 149 250 95 250 16 2% 241 (10.8) 345] 8 patel et al., 2022 111 170 84 170 14.9% 1.93 (1.25, 2.98] Total events 611 529 Heterogenetic, Tutar = 0.15, Chi* = 2.278, df = 7 (P = 0.002); P = 69% Test for overall effect Z = 1.99 (P = 0.05) B. Case Control Odds Ratio Odds Ratio Odds Ratio Odds Ratio Odds Ratio Odds Ratio Odds Ratio Odds Ratio Odds Ratio Odds Ratio M44, Random, 95% CI M44, Rand											
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $									-		
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $											
Total events 611 523 Total events 611 523 Heriorgeneity: Taur = 0.15; Chi* 22.58, dif = 7 ( $\theta$ = 0.002); I* 66%. B. Study or Studgroup Cevents Total Veight MH, Random, 95% Cl Ashnaid et al., 2010 105 105 122 105 105 122 105 105 123 105 105 105 123 105 105 123 105 105 123 105 105 123 105 105 123 105 105 123 105 105 105 123 105 105 123 105 105 105 123 105 105 105 123 105 105 105 123 105 105 105 123 105 105 105 123 105 105 105 105 123 105 105 105 105 105 105 105 105 105 105	o pater et al., 2022		170	04	170	14.370	1.85 [1.25, 2.86]		-		
Heitorgeneity: Taur = 0.15; C/E = 22.78, df = 7 ( $\phi$ = 0.002; ( $P$ = 60%. <b>B.</b> <b>Case</b> Control 0dds Ratio Study of Subgroup Events Total Events Total Weight MLR Random, 95% Cl Multiple Study = 0.000; ( $P$ = 60%. <b>Case</b> Control 0dds Ratio Dimanchandra et al., 2014 12: 21: 11: 618: 21: 21: 22: 11: 11: 10: 20: 11: 81: 10: 20: 11: 82: 10: 20: 20: 20: 20: 20: 20: 20: 20: 20: 2	Total (95% CI)		1381		1463	100.0%	1.41 [1.01, 1.98]		◆		
UDD 1     UDD 1 <th colspan="2" td="" udd<=""><td>Total events</td><td>611</td><td></td><td>529</td><td></td><td></td><td></td><td></td><td></td></th>	<td>Total events</td> <td>611</td> <td></td> <td>529</td> <td></td> <td></td> <td></td> <td></td> <td></td>		Total events	611		529					
UDD 1     UDD 1 <th colspan="2" td="" udd<=""><td>Heterogeneity: Tau<sup>2</sup> = 0.15; (</td><td>Chi<sup>2</sup> = 22.7</td><td>78. df =</td><td>7 (P = 0.)</td><td>002); I<sup>2</sup></td><td>= 69%</td><td></td><td>L</td><td>-<u>t</u> t to 10</td></th>	<td>Heterogeneity: Tau<sup>2</sup> = 0.15; (</td> <td>Chi<sup>2</sup> = 22.7</td> <td>78. df =</td> <td>7 (P = 0.)</td> <td>002); I<sup>2</sup></td> <td>= 69%</td> <td></td> <td>L</td> <td>-<u>t</u> t to 10</td>		Heterogeneity: Tau <sup>2</sup> = 0.15; (	Chi <sup>2</sup> = 22.7	78. df =	7 (P = 0.)	002); I <sup>2</sup>	= 69%		L	- <u>t</u> t to 10
B.         Case         Control         Odds Ratio         Odds Ratio           Study or Stingroup         Events         Total         Events         Total         Weight         M.H., Random, 95% CI         M.H., Random, 95% CI           Ashavaid stal, 2000         105         105         102         192         Not estimable           Dinanschardt ast 2014         172         111         104         1130         70, 138           Madady et al., 2016         111         110         104         Not estimable           Paraskeid, 2016         111         104         104         Not estimable           Paraskeid, al., 2014         215         257         27.1%         0.56 (0.36, 0.97)           Neadesynetal, 2014         125         200         128         200         101, 0.10, 0.81]           Schardner et al., 2014         215         200         238         200         0.31 (0.16, 0.81]           Schardner et al., 2014         127, 0.29         324         0.102, 22.46         0.002, 70.90]         126           Total events         1200         134         40         0.02, 17.83         50.01         10.44         40.92         0.22         134.93         10.14, 14.90         10.43, 0.93         10.								0.01			
$\begin{tabular}{ c c c c c c c c c c c c c c c c c c c$									Favours (case) Favours (control)		
Study or Study coup         Events         Total         Weight         M.H. Random, 95% Cl         M.H. Random, 95% Cl           Abnavia et al., 2010         105         105         192         No testimable           Dhanachandra et al., 2014         172         211         168         211         261, 95, 01         M.H. Random, 95% Cl           M handard at al., 2014         172         211         168         211         261, 95, 01         138         143           M handard at al., 2014         224         252         271, %         0.56 [0.3, 0, 37]         400	В.										
Astrivial et al., 2000     105     105     192     192     192       Dinarchandra et al., 2014     121     186     121     211     182     112     211     182     112     211     182     112     211     182     112     211     182     112     211     182     112     211     182     112     211     182     112     211     182     112     211     182     112     211     182     112     211     210     222     121     211     211     211     211     220     211     220     211     220     211     220     220     220     221     220     220     220     220     220     220     220     220     200     120     200     200     200     200     200     200     200     200     200     200     200     200     200     200     200     200     200     200     200     2											
Dhanacharia et al., 2014 172 211 188 211 261% 1.13 (0.70, 18.3) Oh parchward et al., 2016 166 224 215 257 27.1% 0.56 (0.30, 0.37) M hauday et al., 2018 262 242 251 257 27.1% 0.56 (0.30, 0.37) M hauday et al., 2014 236 240 170 170 2.7% 0.16 (0.17, 0.83) Present study 70 70 109 109 Not estimable Schadrot et al., 2014 215 250 238 220 21.0% 0.31 (0.16, 0.81) Spaket et al., 2012 134 170 150 170 2.2% 0.56 (0.34, 0.92) C. Case Control Weight M.H. Random, 95% CI Athward et al., 2014 162 422 167% 0.39 (0.37, 0.98) Charles Control Weight M.H. Random, 95% CI Athward et al., 2014 162 422 167% 0.39 (0.37, 0.39) Charles Control Weight M.H. Random, 95% CI Athward et al., 2014 162 422 167% 0.39 (0.37, 0.39) Charles Control Weight M.H. Random, 95% CI Athward et al., 2014 162 422 167% 0.39 (0.37, 1.23) Charles Control Control Weight M.H. Random, 95% CI Athward et al., 2014 162 422 167% 0.39 (0.71, 1.23) Charles Control	Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% Cl		M-H, Random, 95% Cl		
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	Ashavaid et al., 2000										
M chadayet al., 2018 111 111 104 104 Not estimable Present tudy 210 236 12 236 240 170 170 2.7% 0.15 [0.01, 2.8] S chadret al., 2014 236 240 170 170 2.7% 0.10 [1.0, 0.10 [1.0, 0.10] S patel et al., 2014 236 256 238 260 21.0% 0.31 [1.0, 0.32] S patel et al., 2012 134 170 150 170 2.2% 0.50 [0.27, 0.90] Total events Total events 1209 1346 Heterogenerity 1.01 (2.0, 0.2), P= 65%. Testfor overall effect Z = 2.30 (P = 0.02), P= 65%. Study or Study or 0.10 (1.0, 0.11	Dhanachandra et al., 2014	172	211	168	211	26.1%	1.13 [0.70, 1.83]				
Panalak et al., 2014 236 240 170 170 2.7% 0.15 [0.01, 2.88] Present study 70 109 Not estimates Schandrad et al., 2014 215 250 238 250 21.0% 0.31 [0.16, 0.61] Schandrad et al., 2014 215 250 238 250 21.0% 0.31 [0.16, 0.61] Sphatel et al., 2021 134 170 150 170 22.2% 0.50 [0.27, 0.90] Total events Total events Test for orenal effect Z = 2.30 (P = 0.02) C. C. Case Control Subgross bibgroup Events Total Weight MH, Pandom, 95% CI MH, Pan	DN parchwani et al., 2018	166	224	215	257	27.1%	0.56 [0.36, 0.87]				
Present tudy 70 70 70 109 109 Not estimate S handre et al., 2012 15 250 238 260 210% 0.31 [0.6, 0.61] S patel et al., 2022 134 170 150 170 23.2% 0.50 [0.27, 0.90] Total events Total events Total events Total events Suby or Subgroup Events Total Verified Total Weight MLH, Random, 95% CI MLH, Ra	M chaudary et al., 2018	111	111	104	104		Not estimable				
8 chandra et al., 2014 215 250 238 250 21.0% 0.31 (0.16.0.61) 8 patel et al., 2022 134 170 150 170 23.2% 0.50 (0.27, 0.30) Total events 1209 1346 Heterogenetity: Taut = 0.19, Ch <sup>2</sup> = 115.3, df = 4.0 <sup>6</sup> = 0.02); t <sup>2</sup> = 65%. Test for overall effect Z = 2.30, t <sup>2</sup> = 0.02) C. C. Control Cont	Patnaik et al., 2014	236	240	170	170	2.7%	0.15 [0.01, 2.88]	<b>←</b>			
S patel et al., 2022 134 170 150 170 23.2% 0.50 (0.27, 0.90) Total (95% Ct) 1381 1463 100.0% 0.56 (0.34, 0.92) Heterogeneity: Tat" = 0.19, Ch" = 15.3, df = 4 (P = 0.02); P = 55% Test for overall effect Z = 2.30 (P = 0.22) C. Case Control Odds Ratio Study or Stubgroup Events Total Weight MLI, Random, 95% Ct Ashavaid et al., 2020 14 210 33 384 10.1% 0.76 (0.40, 1.45) Dinanchandra et al., 2014 152 22 157% 0.39 (0.71, 1.23) Pathalk et al., 2014 152 22 157% 0.39 (0.71, 1.23) Pathalk et al., 2014 152 22 157% 0.39 (0.71, 1.23) Pathalk et al., 2014 152 22 157% 0.39 (0.71, 1.23) Pathalk et al., 2014 152 22 157% 0.39 (0.71, 1.23) Pathalk et al., 2014 152 21 55% 118 0.40, 3.46 (0.56, 77) Pathalk et al., 2014 124 200 0.167% 0.17 (0.30, 1.85) Studet et al., 2014 124 500 107 500 16.7% 2.14 (1.62, 2.83) Scharder et al., 2014 124 2.406 et al. 156% 1.78 (1.78, 1.77) (1.26, 2.27) Total (95% Ct) 2762 2926 100.0% 1.38 (1.02, 1.85) Total events 73 646	Present study	70	70	109	109		Not estimable				
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	S chandra et al., 2014	215	250	238	250	21.0%	0.31 [0.16, 0.61]				
Total events         1209         1346           Hetrogenetity, Tuar = 0.10; ChP = 1.05; dF = 60 = 0.02; P = 65%.         0.05         0.02         0.05         0.02         20           C.         Study or Study coup         Centrol         Odds Ratio         0.005 (MH, Random, 95% Cl         MH, Random, 95% Cl </td <td>S patel et al., 2022</td> <td>134</td> <td>170</td> <td>150</td> <td>170</td> <td>23.2%</td> <td>0.50 [0.27, 0.90]</td> <td></td> <td></td>	S patel et al., 2022	134	170	150	170	23.2%	0.50 [0.27, 0.90]				
Total events         1209         1346           Hebrogeneiky: Taur = 0.19; ChP = 1.53; d = 4 (P = 0.02); P = 65%.         0.05 <t< td=""><td>Total (95% CI)</td><td></td><td>1381</td><td></td><td>1463</td><td>100.0%</td><td>0.56 [0.34, 0.92]</td><td></td><td>•</td></t<>	Total (95% CI)		1381		1463	100.0%	0.56 [0.34, 0.92]		•		
Heterogeneity: Taur = 0.19; Chi = 11.53, df = 4 ( $\varphi = 0.02$ ); P = 65%. Testfor overall effect Z = 2.30; df = 0.02; Testfor overall effect Z = 2.30; df = 0.02; C. Study of Study of Study or Study o		1209		1346					•		
UUS 52 200 (P = 0.02)         UUS 52 200 (P = 0.02)         20           C.           Case         Odds Ratio         Odds Ratio         Odds Ratio           Nuty or Stuty			53 df=		02): I <sup>2</sup> =	65%		$\rightarrow$			
C.         Case         Control         Odds Ratio         Odds Ratio           Study or Sthgroup         Events         Total         Events         Total         Weight         M.H., Random, 95% CI         M.H., Random, 95% CI           Ashavaid tal., 2000         14         210         33         384         10.1%         0.76 [0.40, 1.45]           Dinaschandra tal., 2014         162         222         16.7%         0.71 [0.30, 1.65]         H.H., Random, 95% CI           Minadary et al., 2016         10.222         13         208         7.6%         O.TI [0.30, 1.65]           Pahaskeit al., 2014         44         490         13         340         10.3%         2.54 [1.35, 4.79]           Present study         6         140         82         16.9%         7.5%         7.11 [1.04, 0.346]           Schandra et al., 2014         184         50%         11.09         16.7%         2.14 [1.62, 2.83]           Schalet et al., 2021         127         340         16.0%         1.58 [1.02, 1.85]         1.44           Fostel et al., 2021         147         340         16.0%         1.58 [1.02, 1.85]         1.44           Fostel et al., 2021         127         340         16.0%         1.58 [1.02, 1.85]         <					//			0.05			
Case         Control         Odds Ratio         Odds Ratio           Study of Studycous         Evends         Total Evend	C								ravours (case) ravours (control)		
Study or Study or U         Events         Total         Weight         M.H., Random, 95% CI         M.H., Random, 95% CI           Anhraid etal, 2001         14         10         33         44         101%         076         407.14         103         34         101%         076         407.14         103	С.	-									
Astaviardi et al., 2000         14         210         33         344         101 %         0.76 [0.0, 1.45]           Dinanchandra et al., 2014         124         216         422         169         403 [0.7], 1.23           Dinanchandra et al., 2014         124         216         422         169         411, 11, 11, 11, 100]           Minandary et al., 2018         1022         13         208         7.6%         0.71 [0.30, 1.65]           Pahnake et al., 2014         44         490         13         340         10.3%         2.54 [1.36, 4.79]           Present study         6         140         82         55%         1.18 [0.40, 3.46]	Church and Carls area un					Mainlat					
Dhanacharia et al., 2014 162 422 167 % 0.93 (0.71, 123) M chauday et al., 2018 216 448 199 514 171 % 1.747 [14, 130] M chauday et al., 2018 216 448 199 514 171 % 1.747 [14, 130] M chauday et al., 2018 216 448 199 514 171 % 1.747 [14, 130] Present study 6 140 13 % 2.541 55, 479] Present study 6 140 18 218 55% 1.19 [0.03, 346] S chaudra et al., 2014 44 450 13 % 2.541 (55, 479] Present study 6 140 19 167 % 2.14 [16, 2, 237] Total events 783 646 Total events 783 8.646 7 (P = 0.0002); P = 75% 0.022 0.1 1 05									M-H, Kandolii, 95% Cl		
DN parchwani et al., 2018 216 448 199 514 17.1% 1.47 [1.14, 1.90] Mandariy et al., 2018 10 222 13 208 76% 0.71 [0.30, 1.65] Pahnake et al., 2014 44 490 13 340 10.3% 2.54 [1.36, 4.79] Present study 61 40 8 218 55% 1.18 [0.40, 3.46] Schandrat et al., 2014 194 500 10.7500 16.7% 2.14 [1.62, 2.83] Spatiel et al., 2014 194 500 10.0% 1.57 [1.26, 2.23] Total events Total events											
M chandary et al, 2018 10 222 13 208 7.6% 0.71 (0.30, 1.65) Present study 10 44 440 13 340 103% 2.54 (1.55, 479) Present study 6 140 8 218 55% 1.59 (1.36, 379) S chandra et al, 2014 44 500 107 500 157% 2.24 (1.52, 237) S patel et al, 2022 147 340 104 340 16.0% 1.73 (1.26, 2.37) Total events 733 646 Hearogeneity, Tar" = 0.12, Ch <sup>2</sup> = 28.06, et = 7 (P = 0.0002); P = 75% 0.022 0.1 10 5									1+		
Parhask et al. 2014 44 460 13 340 10.3% 2.54 (1.38, 4.79) Present study 6 140 8 218 55% 1.16 (0.40, 3.46) S chandra et al., 2014 184 500 107 500 18.7% 2.14 (1.62, 2.83) S patel et al., 2014 194 500 10.0% 1.73 (1.26, 2.83) Total (95% C) 2.762 2926 100.0% 1.73 (1.26, 2.83) Total events 782 306, df = 7 (P = 0.0002); P = 75% 0.0022, 0 1 10 5											
Present study 6 140 8 218 55% 118 [0.41] 346] 5 chandra etal , 2011 84 500 107 500 167% 2214 [6.2, 283] 5 patel et al, 2022 147 340 104 340 16.0% 1.73 [1.26, 2.37] Total 95% Ct) 2762 2926 100.0% 1.38 [1.02, 1.85] Total sevents - 2, CHP = 28.06, eff = 7 (P = 0.0002); P = 75% 0.02 0.1 1 10 5											
S chandre et al., 2014 194 500 107 500 167% 2.14 (102, 2.83) S phatel et al., 2022 147 340 104 340 16.0% 1.73 (12.62, 2.37) Total (95% C) 2762 2926 100.0% 1.73 (12.62, 2.37) Total events 783 Total events 1.74 = 0.12, Ch <sup>2</sup> = 2.806, df = 7 (7 = 0.0002); P = 75% 0.002 0.1 10 5											
S patel et al., 2022 147 340 104 340 16.0% 1.73 (1.26, 2.37) Total (95% Ct) 2762 2926 100.0% 1.38 (1.02, 1.85) Total vents 7 20 200 100.0% 1.38 (1.02, 1.85) Heterogeneity, Tauri e 0.1, 2014 28.06, df = 7 (P = 0.0002), P = 75% 0.02 0.1 10 5									-		
Total (95% CI) 2762 2926 100.0% 1.38 [1.0.2, 1.85] Total events 783 646 Heterogeneeky: Tau# = 0.12; (№ = 28.06; df = 7 (P = 0.0002); № = 75% Total fear unit 1 = 0.4 (II = 0.0002); № = 75%											
Total events 783 646 Heterogeneity, Tau <sup>#</sup> = 0.12; Chi <sup>#</sup> = 28.06, df = 7 (P = 0.0002); I <sup>#</sup> = 75% Disclose avenuit (Review 1 = 0.01, 0.00) = 0.01 1 10 5	o pater et al., 2022	147	34U	104	34U	10.0%	1.73 [1.26, 2.37]				
Heterogeneity: Tau" = 0.12; Chi" = 28.06; df = 7 (P = 0.0002); i" = 75%	Total (95% CI)		2762		2926	100.0%	1.38 [1.02, 1.85]		◆		
Test for event of test 7 = 2.44 (P = 0.04) 0.02 0.1 1 10 5	Total events	783		646							
	Heterogeneity: Tau <sup>2</sup> = 0.12; (	Chi <sup>2</sup> = 28.0	06, df=	7 (P = 0.)	0002);	I²= 75%		L			
	Test for overall effect: Z = 2.1	1 (P = 0.0	4)					0.02	Favours [case] Favours [control]		

Figure 2. Forest plot showing individual and pooled ORs (95% CI) of the risk for AT1R A1166C polymorphism with hypertension and controls. A. Dominant model (AA versus AC+CC). B. Recessive model (CC versus AC+AA). C. Allelic model (C versus A).

Table 3. The distribution of AT1R A1166C genotypes and alleles for cases and controls among Indian populations

Author (Reference)		Genotypes						Allele frequency					
	Genotyping method	Case				Control			Case		Control		<b>P</b> ª
		AA	AC	сс	AA	AC	сс	А	С	Α	С	-	
Ashavaid et al (17)	PCR-RFLP	91 (87)	14 (13)	0	159 (83)	33 (17)	0	196 (93)	14 (7)	351 (91)	33 (9)	0.1927	1.69
Chandra et al (12)	PCR-RFLP	101 (40)	114 (46)	35 (14)	155 (62)	83 (33)	12 (5)	316 (63)	184 (37)	393 (79)	107 (21)	0.8359	0.04
Parchwani et al (14)	PCR-RFLP	66 (29)	100 (45)	58 (26)	100 (39)	115 (45)	42 (16)	232 (52)	216 (48)	315 (61)	199 (39)	0.3606	0.83
Patnaik et al (15)	PCR-RFLP	200 (83)	36 (15)	4 (2)	157 (92)	13 (8)	0	436 (91)	44 (9)	327 (96)	13 (4)	0.6042	0.26
Chaudhary and Chaudhary (16)	PCR-RFLP	101 (91)	10 (9)	0	91 (88)	13 (12)	0	212 (95)	10 (5)	195 (94)	13 (6)	0.4966	0.46
Patel et al (19)	PCR-RFLP	59 (35)	75 (44)	36 (21)	86 (50)	64 (38)	20 (12)	193 (57)	147 (43)	236 (70)	104 (30)	0.1392	2.18
Dhanachandra et al (18)	PCR-RFLP	88 (42)	84 (40)	39 (18)	85 (40)	83 (39)	43 (21)	260 (62)	162 (38)	253 (60)	169 (40)	0.0086	6.89
Present study	PCR-RFLP	64 (91)	6 (9)	0	14 (93)	1(7)	0	134 (96)	6 (4)	29 (97)	1 (3)	0.8938	0.01

HWE, Hardy-Weinberg equilibrium.

<sup>a</sup> Chi-square test.

5




Figure 3. Funnel plots of publication biases on the relationship of AT1R A1166C polymorphism. Each point indicates the individual study included in the meta-analysis. (A. Dominant model, B. Recessive model, C. Allelic model).

populations (20), Calabar and Uyo (8), Sardinian (21), Jordanian (22), and Hispanic populations (23), showed no association between AT1R gene polymorphism and hypertension. On contrary, studies from Turkish (24), Polish (25), Lebanese (26), and Brazilian populations (27) revealed a significant interrelation between AT1R gene polymorphism and hypertension risks.

The support for the AT1R A1166C gene polymorphism in connection to hypertension has been strengthened by a meta-analysis study. A previous meta-analysis conducted by Liu et al, with 28952 individuals from Asian and Caucasian populations found a significant association (28). Further, Wang et al, from Chinese population with 11601 individuals revealed a significant association (29). Furthermore, the meta-analysis by Yang et al, with 22857 individuals (30), Fajar et al, with 13251 individuals (31), and Niu and Qi (32) with 16474 individuals in an all-ethnicity populations found a significant difference between the AT1R A1166C with essential hypertension. Likewise, our meta-analysis observed a significant association between hypertension and AT1R gene polymorphism. In contradiction, Li et al, with 8493 individuals revealed that there was no significant correlation between the AT1R gene polymorphisms with pregnancy induced hypertension (33).

The mechanism underlying the relationship of essential hypertension with the AT1R A1166C polymorphism has been investigated since the 1166 A/C polymorphism is positioned in 3' UTR. Angiotensinogen produces angiotensin-I with the presence of renin, and the angiotensin-converting enzyme then catalyzes the synthesis of active angiotensin II. Ang II affects the morphology and function of major arteries by binding to AT1R and controlling inflammation, extracellular matrix deposition, and cell proliferation, these affect the density of AT1R though the polymorphism is present in the noncoding region (34). The AT1R A1166C polymorphism can reduce the ability of microRNA-155 to bind in the specific 3'UTR sequence, which can result in the onset of hypertension by the up-regulation of AT1R (35) . In spontaneously hypertensive rats and human aortic smooth muscle cells, oxidative stress was discovered to be a factor in the up-regulation of the vascular AT1R through the nuclear factor-kB (NF-kB) signaling pathway. Following restoring AT1R expression to baseline, pyrrolidine dicarbamate treatment, an NF-kB inhibitor, drastically slowed the hypertension progression in spontaneously hypertensive rats (36). In all central nervous tissues, including the spinal cord, and other functional areas of the brain in spontaneously hypertensive rats, the AT1R gene expression was favorably correlated with blood pressure (35). A recent study revealed that maternal exercise affected the offspring's mesenteric artery through the repression of the AGTR1 gene, by upregulating the expression of DNA methyltransferase in the spontaneously hypertensive rats and significantly reducing hypertension (37). Besides, it was noted in the study (38) that increased blood pressure is associated with high-fat diets, AT1R expression in the kidney and aorta were both upregulated in mice with the ingestion of high-fat high-sucrose diets, results yielded that utilization of berry lowered AT1R expression in kidney and aorta, resulting in reduced renal NADPH oxidases (NOX) and lessening the oxidative stress in endothelium reduces hypertension which is driven by the polyphenols present in the berries.

# Conclusion

In conclusion, the study on AT1R A1166C polymorphism revealed no significant association in South Indian hypertensives. However, this meta-analysis illustrates that AT1R A1166C polymorphism significantly increases hypertension risk in dominant, recessive, and allelic models. The Indian population showed the presence of the C allele and the AC genotype is associated with a higher risk of hypertension. Further, studies could be extended to a larger number of hypertensive individuals to gain more evidence. Thus, offering an index of those who are 'at risk' and estimating the likelihood that they would develop hypertension in the future may be a powerful predictive classifier. The ability to classify hypertensive people according to their genetic makeup will assist in personalizing medication and expanding treatment options, and these studies can further support translational research.

#### Limitations of the study

Present research has some limitations. First, essential factors which regulate hypertension such as, body mass index, physical activity and other lifestyle characteristics were not considered to correlate with our findings. Second, the sample size included for this study was very small. Therefore, large number of samples with all essential factors are to be correlated to confirm our findings.

#### Acknowledgments

The authors would like the pay sincere thanks to the management of Sri Ramachandra Institute of Higher Education and Research (SRIHER), Chennai, and Vellore Institute of Technology, Vellore for providing the necessary facilities for this work.

#### Authors' contribution

**Conceptualization:** Sandhya Suresh and Gnanasambandan Ramanathan.

Investigation: AR, Sandhya Suresh, Ramprasad Elumalai.

**Data curation:** Harini Ravi and Gnanasambandan Ramanathan

Visualization: Gnanasambandan Ramanathan.

Writing-original draft: Amulya Ramakrishnegowda and Harini Ravi.

Writing-review and editing: Ramprasad Elumalai, Harini Ravi and Gnanasambandan Ramanathan.

**Project administration:** Sandhya Suresh and Gnanasambandan Ramanathan.

#### **Conflicts of interest**

The authors declare that there is no conflict of interest.

### **Ethical issues**

The research followed the tenets of the Declaration of Helsinki. The Institutional Ethics Committee of Sri Ramachandra Medical College and Research Institute (SRIHER) approved the study protocols (IEC No: IEC-NI/09/MAR/08/09). After approval, upon written informed consent the 3 ml of blood sample was collected from all study participants. Ethical issues (including plagiarism, data fabrication, double publication) have been completely observed by the authors.

#### **Funding/Support**

None

#### References

- Ruster C, Wolf G. Renin-angiotensin-aldosterone system and progression of renal disease. J Am Soc Nephrol. 2006;17:2985-91. doi: 10.1681/ASN.2006040356.
- 2. Miller JA, Scholey JW. The impact of renin-angiotensin system polymorphisms on physiological and pathophysiological processes in humans. Curr Opin Nephrol Hypertens. 2004;13:101-6. doi: 10.1097/00041552-200401000-00014.
- Bonnardeaux A, Davies E, Jeunemaitre X, Fery I, Charru A, Clauser E, et al. Angiotensin II type 1 receptor gene polymorphisms in human essential hypertension. Hypertension. 1994;24:63-9. doi: 10.1161/01.hyp.24.1.63.

- 4. Sethupathy P, Borel C, Gagnebin M, Grant GR, Deutsch S, Elton TS, et al. Human microRNA-155 on chromosome 21 differentially interacts with its polymorphic target in the AGTR1 3' untranslated region: a mechanism for functional single-nucleotide polymorphisms related to phenotypes. Am J Hum Genet. 2007;81:405-13. doi: 10.1086/519979.
- Kainulainen K, Perola M, Terwilliger J, Kaprio J, Koskenvuo M, Syvanen AC, et al. Evidence for involvement of the type 1 angiotensin II receptor locus in essential hypertension. Hypertension. 1999;33:844-9. doi: 10.1161/01.hyp.33.3.844.
- Agachan B, Isbir T, Yilmaz H, Akoglu E. Angiotensin converting enzyme I/D, angiotensinogen T174M-M235T and angiotensin II type 1 receptor A1166C gene polymorphisms in Turkish hypertensive patients. Exp Mol Med. 2003;35:545-9 doi: 10.1038/emm.2003.71.
- Kikuya M, Sugimoto K, Katsuya T, Suzuki M, Sato T, Funahashi J, et al. A/C1166 gene polymorphism of the angiotensin II type 1 receptor (AT1) and ambulatory blood pressure: the Ohasama Study. Hypertens Res. 2003;26:141-5. doi: 10.1291/hypres.26.141.
- Kooffreh ME, Anumudu CI, Duke R, Okpako EC, Kumar PL. Angiotensin II type 1 receptor A1166C gene polymorphism and essential hypertension in Calabar and Uyo cities, Nigeria. Indian J Hum Genet. 2013;19:213-8. doi: 10.4103/0971-6866.116120.
- Li N, Li T, Wang X, Zu F, Wang J, Zhang D, et al. The study for relationship between the angiotensin II type 1 receptor gene polymorphism and essential hypertension in kazakans of Xinjiang. Heart. 2010;96:A8. doi: 10.1136/ hrt.2010.208967.23.
- Sugimoto K, Katsuya T, Ohkubo T, Hozawa A, Yamamoto K, Matsuo A, et al. Association between angiotensin II type 1 receptor gene polymorphism and essential hypertension: the Ohasama Study. Hypertens Res. 2004;27:551-6. doi: 10.1291/hypres.27.551.
- Ramu GU, Shewade DG, Swaminathanb RP, Dutta TK, Balachander J, Adithan C. Candidate Gene Polymorphisms of Renin Angiotensin System and Essential Hypertension in a South Indian Tamilian Population. Int J Hum Genet. 2011;11:31-40. doi: 10.1080/09723757.2011.11886120.
- Chandra S, Narang R, Sreenivas V, Bhatia J, Saluja D, Srivastava K. Association of angiotensin II type 1 receptor (A1166C) gene polymorphism and its increased expression in essential hypertension: a case-control study. PLoS One. 2014;9:e101502 doi: 10.1371/journal.pone.0101502.
- Sambrook J RD. Molecular cloning: a laboratory manual. 3rd ed. Cold Spring Harbor Laboratory Press; 2001.
- Parchwani DN, Patel DD, Rawtani J, Yadav D. Analysis of Association of Angiotensin II Type 1 Receptor Gene A1166C Gene Polymorphism with Essential Hypertension. Indian J Clin Biochem. 2018;33:53-60 doi: 10.1007/s12291-017-0644-7.
- 15. Patnaik M, Pati P, Swain SN, Mohapatra MK, Dwibedi B, Kar SK, et al. Aldosterone synthase C-344T, angiotensin II type 1 receptor A1166C and 11- $\beta$  hydroxysteroid dehydrogenase G534A gene polymorphisms and essential hypertension in the population of Odisha, India. 2014;93:799-808. doi: 10.1007/s12041-014-0464-y.
- Chaudhary M, Chaudhary SJPIJ. Lifestyle and related genetic variations influence susceptibility towards essential hypertension. Pharma Innovation. 2018;7:560-568.

- Ashavaid TF, Shalia KK, Nair KG, Dalal JJ. ACE and AT1R gene polymorphisms and hypertension in Indian population. J Clin Lab Anal. 2000;14:230-7. doi: 10.1002/1098-2825(2000)14:5<230::AID-JCLA6>3.0.CO;2-U.
- Dhanachandra Singh K, Jajodia A, Kaur H, Kukreti R, Karthikeyan M. Gender specific association of RAS gene polymorphism with essential hypertension: a casecontrol study. Biomed Res Int. 2014;2014:538053 doi: 10.1155/2014/538053.
- Patel S, Sharma H, Sharma S, Rao D, Dholakia J, Baraiya H. Angiotensin II type I receptor gene polymorphism in essential hypertensive and normotensive subjects. Int J Clin Biochem Res 2022;9:322-327. doi: 10.18231/j. ijcbr.2022.063.
- El-Banawy H, Bedair R, Mohammed A. Angiotensin II type 1 receptor (A1166C) gene polymorphism in Egyptian adult hemodialysis patients. Alexandria Journal of Medicine. 2015;51:339-345. doi:10.1016/j.ajme.2014.12.003.
- Filigheddu F, Argiolas G, Bulla E, Troffa C, Bulla P, Fadda S, et al. Clinical variables, not RAAS polymorphisms, predict blood pressure response to ACE inhibitors in Sardinians. Pharmacogenomics. 2008;9:1419-27. doi: 10.2217/14622416.9.10.1419.
- 22. Shahin DS, Irshaid YM, Saleh AA. The A(1166)C polymorphism of the AT1R gene is associated with an early onset of hypertension and high waist circumference in Jordanian males attending the Jordan University Hospital. Clin Exp Hypertens. 2014;36:333-9 doi: 10.3109/10641963.2013.827698.
- Bautista LE, Vargas CI, Orostegui M, Gamarra G. Population-based case-control study of renin-angiotensin system genes polymorphisms and hypertension among Hispanics. Hypertens Res. 2008;31:401-8 doi: 10.1291/ hypres.31.401.
- Bayramoglu A, Kurt H, Gunes HV, Ata N, Birdane A, Dikmen M, et al. Angiotensin II type 1 receptor (AT1) gene A1166C is associated with the risk of hypertension. Genet Test Mol Biomarkers. 2015;19:14-7 doi: 10.1089/ gtmb.2014.0233.
- 25. Dzida G, Sobstyl J, Puzniak A, Golon P, Mosiewicz J, Hanzlik J. Polymorphisms of angiotensin-converting enzyme and angiotensin II receptor type 1 genes in essential hypertension in a Polish population. Med Sci Monit. 2001;7:1236-41.
- Saab YB, Gard PR, Overall AD. The association of hypertension with renin-angiotensin system gene polymorphisms in the Lebanese population. J Renin Angiotensin Aldosterone Syst. 2011;12:588-94 doi: 10.1177/1470320311408465.
- Freitas SR, Cabello PH, Moura-Neto RS, Dolinsky LC, Lima AB, Barros M, et al. Analysis of renin-angiotensinaldosterone system gene polymorphisms in resistant hypertension. Braz J Med Biol Res. 2007;40:309-16. doi: 10.1590/s0100-879x2007000300005.
- 28. Liu DX, Zhang YQ, Hu B, Zhang J, Zhao Q. Association

of AT1R polymorphism with hypertension risk: An update meta-analysis based on 28,952 subjects. J Renin Angiotensin Aldosterone Syst. 2015;16:898-909. doi: 10.1177/1470320315584096.

- 29. Wang JL, Li X, Hao PP, Feng X, Chen YG, Yun Z. Angiotensin II type 1 receptor gene A1166C polymorphism and essential hypertension in Chinese: a meta-analysis. J Renin Angiotensin Aldosterone Syst. 2010;11:127-35. doi: 10.1177/1470320310364181.
- 30. Yang Y, Tian T, Lu J, He H, Xing K, Tian G. A1166C polymorphism of the angiotensin II type 1 receptor gene contributes to hypertension susceptibility: evidence from a meta-analysis. Acta Cardiol. 2017;72:205-15. doi: 10.1080/00015385.2017.1291211.
- 31. Fajar JK, Susanti M Pikir. The association between angiotensin II type 1 receptor A1166C gene polymorphism and the risk of essential hypertension: a meta-analysis. Egypt J Med Hum Genet. 2019;20:14. doi: 10.1186/s43042-019-0016-3.
- Niu W, Qi Y. Association of the angiotensin II type I receptor gene +1166 A>C polymorphism with hypertension risk: evidence from a meta-analysis of 16474 subjects. Hypertens Res. 2010;33:1137-43. doi: 10.1038/hr.2010.156.
- 33. Li Y, Zhu M, Hu R, Yan W. The effects of gene polymorphisms in angiotensin II receptors on pregnancy-induced hypertension and preeclampsia: a systematic review and meta-analysis. Hypertens Pregnancy. 2015;34:241-60. doi: 10.3109/10641955.2015.1009543.
- Stankovic A, Kolakovic A, Zivkovic M, Djuric T, Bundalo M, Koncar I, et al. Angiotensin receptor type 1 polymorphism A1166C is associated with altered AT1R and miR-155 expression in carotid plaque tissue and development of hypoechoic carotid plaques. Atherosclerosis. 2016;248:132-9 doi: 10.1016/j.atherosclerosis.2016.02.032.
- 35. Ceolotto G, Papparella I, Bortoluzzi A, Strapazzon G, Ragazzo F, Bratti P, et al. Interplay between miR-155, AT1R A1166C polymorphism, and AT1R expression in young untreated hypertensives. Am J Hypertens. 2011;24:241-6 doi: 10.1038/ajh.2010.211.
- 36. Bhatt SR, Lokhandwala MF, Banday AA. Vascular oxidative stress upregulates angiotensin II type I receptors via mechanisms involving nuclear factor kappa B. Clin Exp Hypertens. 2014;36:367-73 doi: 10.3109/10641963.2014.943402.
- Shan M, Li S, Zhang Y, Chen Y, Zhou Y, Shi L. Maternal exercise upregulates the DNA methylation of Agtr1a to enhance vascular function in offspring of hypertensive rats. Hypertens Res. 2023;46(3):654-666. doi: 10.1038/s41440-022-01124-7.
- Meister ML, Najjar RS, Danh JP, Knapp D, Wanders D, Feresin RG. Berry consumption mitigates the hypertensive effects of a high-fat, high-sucrose diet via attenuation of renal and aortic AT(1)R expression resulting in improved endothelium-derived NO bioavailability. J Nutr Biochem. 2023;112:109225. doi: 10.1016/j.jnutbio.2022.109225.

**Copyright** © 2024 The Author(s); Published by Nickan Research Institute. This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

8